



Financial Statements

Canadian Liver Foundation

December 31, 2018

Contents

	Page
Independent Auditor's Report	1 - 2
Statement of Operations	3
Statement of Fund Balances	4
Statement of Financial Position	5
Statement of Cash Flows – General Fund	6
Notes to the Financial Statements	7 - 14
Schedule of Research Trust Funds	15 - 16

Independent Auditor's Report

Grant Thornton LLP
11th Floor
200 King Street West, Box 11
Toronto, ON
M5H 3T4
T +1 416 366 0100
F +1 416 360 4949

To the Directors of
Canadian Liver Foundation

Qualified opinion

We have audited the financial statements of Canadian Liver Foundation (“the Foundation”), which comprise the statement of financial position as at December 31, 2018, and the statements of operations, fund balances and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the possible effects of the matter described in the *Basis for Qualified Opinion* section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of the Canadian Liver Foundation as at December 31, 2018 and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for qualified opinion

In common with many not-for-profit and charitable organizations, the Foundation derives chapter and other revenues directly from the public, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, verification of these revenues was limited to the amounts recorded in the records of the Foundation. Therefore, we were not able to determine whether any adjustments might be necessary to revenue, excess of revenue over expenditure, and cash flows from operations for the years ended December 31, 2018 and 2017, current assets as at December 31, 2018 and 2017, and fund balances as at December 31, 2018 and 2017. Our audit opinion on the financial statements for the year ended December 31, 2018 was modified accordingly because of the possible effects of this limitation in scope.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Foundation in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

The logo for Grant Thornton LLP, featuring the company name in a stylized, cursive script font.

Toronto, Canada
May 27, 2019

Chartered Professional Accountants
Licensed Public Accountants

Canadian Liver Foundation

Statement of Operations

Year ended December 31

	General Fund		Research Trust Funds (Note 2)		Medical Research Fund		Total	
	2018	2017	2018	2017	2018	2017	2018	2017
Revenue								
Donations								
Unrestricted	\$ 2,752,434	\$ 2,865,320	\$ -	\$ -	\$ -	\$ -	\$ 2,752,434	\$ 2,865,320
Restricted	-	-	2,080,065	2,105,911	-	-	2,080,065	2,105,911
Chapter revenue								
Unrestricted	1,760,766	1,541,873	-	-	-	-	1,760,766	1,541,873
Gaming	232,881	74,921	-	-	-	-	232,881	74,921
Restricted	-	-	100,000	350,000	-	-	100,000	350,000
Interest, dividends and realized capital gains	98,247	110,064	202,363	208,371	7,017	12,729	307,627	331,164
Unrealized gain (loss) on investments	(69,833)	28,261	(203,551)	77,258	(40,129)	16,036	(313,513)	121,555
	<u>4,774,495</u>	<u>4,620,439</u>	<u>2,178,877</u>	<u>2,741,540</u>	<u>(33,112)</u>	<u>28,765</u>	<u>6,920,260</u>	<u>7,390,744</u>
Expenditure								
Programs (Note 9)								
Chapter	227,958	239,786	-	-	-	-	227,958	239,786
Gaming	18,678	9,709	-	-	-	-	18,678	9,709
Education	762,977	816,778	-	-	-	-	762,977	816,778
Public information	447,359	471,369	-	-	-	-	447,359	471,369
Research grants and programs								
Graduate studentships	-	-	-	-	16,667	70,000	16,667	70,000
Operating grants	-	-	-	-	389,999	329,999	389,999	329,999
Summer studentships	-	-	-	-	4,000	12,000	4,000	12,000
CanHepC	-	-	112,495	718,887	-	-	112,495	718,887
CASL	-	-	362,717	340,109	-	-	362,717	340,109
Canadian Liver Meeting	-	-	379,881	119	-	-	379,881	119
CaNAL CLF	-	-	268,530	119,071	-	-	268,530	119,071
CCC-CLF	-	-	72	72	-	-	72	72
CLF-CNTRP	-	-	293,319	455,717	-	-	293,319	455,717
CLF-Sexton Liver Cancer Research	-	-	-	-	-	57,000	-	57,000
CLTN-CLF	-	-	2,872	27,068	-	-	2,872	27,068
CLF Krahn Research	-	-	350,000	400,000	-	-	350,000	400,000
CLF – RECAP	-	-	2	-	-	-	2	-
HepB Study Group	-	-	260,786	5,002	-	-	260,786	5,002
Liver Transplant Research	-	-	-	-	100,000	175,000	100,000	175,000
MUHC	-	-	-	1,983	-	-	-	1,983
Team Grant in Liver Cancer	-	-	-	-	200,000	200,000	200,000	200,000
Other	-	-	-	-	1,569	2,919	1,569	2,919
Operating								
Fundraising	1,568,353	1,727,208	-	-	-	-	1,568,353	1,727,208
Administration	1,401,543	1,284,802	-	-	-	-	1,401,543	1,284,802
	<u>4,426,868</u>	<u>4,549,652</u>	<u>2,030,674</u>	<u>2,068,028</u>	<u>712,235</u>	<u>846,918</u>	<u>7,169,777</u>	<u>7,464,598</u>
Excess (deficiency) of revenue over expenditure	\$ 347,627	\$ 70,787	\$ 148,203	\$ 673,512	\$ (745,347)	\$ (818,153)	\$ (249,517)	\$ (73,854)

See accompanying notes to the financial statements.

Canadian Liver Foundation

Statement of Fund Balances

Year ended December 31

	General Fund		Research Trust Funds (Note 2)		Medical Research Fund		Total	
	<u>2018</u>	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>	<u>2017</u>
Fund balance, beginning of year	\$ 1,279,772	\$ 1,665,138	\$ 3,918,805	\$ 3,357,293	\$ 1,402,966	\$ 1,652,966	\$ 6,601,543	\$ 6,675,397
Excess (deficiency) of revenue over expenditure for the year	347,627	70,787	148,203	673,512	(745,347)	(818,153)	(249,517)	(73,854)
Interfund transfers to support activities of the Medical Research Fund	(181,345)	(456,153)	(117,500)	(112,000)	298,845	568,153	-	-
Fund balance, end of year	\$ 1,446,054	\$ 1,279,772	\$ 3,949,508	\$ 3,918,805	\$ 956,464	\$ 1,402,966	\$ 6,352,026	\$ 6,601,543

The following is a summary of the above funds as at December 31 classified as restricted, unrestricted and committed:

	<u>2018</u>	<u>2017</u>
Externally restricted Research Trust Funds (Pages 15 - 16)	\$ 3,949,508	\$ 3,918,805
Committed for research (Note 6)	956,464	1,402,966
General fund		
Geographically restricted (Note 3)	215,822	65,211
Unrestricted funds	1,230,232	1,214,561
	1,446,054	1,279,772
	\$ 6,352,026	\$ 6,601,543

See accompanying notes to the financial statements.

Canadian Liver Foundation

Statement of Financial Position

As at December 31,

	General Fund		Research Trust Funds (Note 2)		Medical Research Fund		Total	
	2018	2017	2018	2017	2018	2017	2018	2017
Assets								
Current								
Cash (Note 3)	\$ 701,522	\$ 163,069	\$ 906,336	\$ 654,661	\$ 129,999	\$ 639,200	\$ 1,737,857	\$ 1,456,930
Accounts receivable	116,023	205,117	-	221,963	-	-	116,023	427,080
Prepaid expenses	11,259	22,855	-	-	-	-	11,259	22,855
	<u>828,804</u>	<u>391,041</u>	<u>906,336</u>	<u>876,624</u>	<u>129,999</u>	<u>639,200</u>	<u>1,865,139</u>	<u>1,906,865</u>
Investments (Note 4)	783,877	1,097,116	3,043,172	3,042,181	826,465	763,766	4,653,514	4,903,063
Capital assets (Note 5)	<u>64,073</u>	<u>79,019</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>64,073</u>	<u>79,019</u>
	<u>\$ 1,676,754</u>	<u>\$ 1,567,176</u>	<u>\$ 3,949,508</u>	<u>\$ 3,918,805</u>	<u>\$ 956,464</u>	<u>\$ 1,402,966</u>	<u>\$ 6,582,726</u>	<u>\$ 6,888,947</u>
Liabilities								
Current								
Payables and accruals	\$ 173,717	\$ 209,700	\$ -	\$ -	\$ -	\$ -	\$ 173,717	\$ 209,700
Deferred lease inducement	20,721	20,721	-	-	-	-	20,721	20,721
	<u>194,438</u>	<u>230,421</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>194,438</u>	<u>230,421</u>
Deferred lease inducement	36,262	56,983	-	-	-	-	36,262	56,983
	<u>230,700</u>	<u>287,404</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>230,700</u>	<u>287,404</u>
Fund balances	<u>1,446,054</u>	<u>1,279,772</u>	<u>3,949,508</u>	<u>3,918,805</u>	<u>956,464</u>	<u>1,402,966</u>	<u>6,352,026</u>	<u>6,601,543</u>
	<u>\$ 1,676,754</u>	<u>\$ 1,567,176</u>	<u>\$ 3,949,508</u>	<u>\$ 3,918,805</u>	<u>\$ 956,464</u>	<u>\$ 1,402,966</u>	<u>\$ 6,582,726</u>	<u>\$ 6,888,947</u>

Commitments (Notes 6 and 7)

On behalf of the Board

Director

Director

See accompanying notes to the financial statements.

Canadian Liver Foundation

Statement of Cash Flows – General Fund

Year ended December 31

2018

2017

Increase (decrease) in cash

Operating		
Excess of revenue over expenditure for the year	\$ 347,627	\$ 70,787
Interfund transfer	(181,346)	(456,153)
Amortization	20,439	20,638
Unrealized loss (gain) on investments	<u>69,833</u>	<u>(28,261)</u>
	256,553	(392,989)
Change in non-cash operating assets and liabilities		
Accounts receivable	89,093	(73,363)
Prepaid expenses	11,593	840
Payables and accruals	<u>(35,985)</u>	<u>18,630</u>
	321,254	(446,882)
Financing		
Deferred lease inducement	<u>(20,721)</u>	<u>(20,721)</u>
Investing		
Purchase of investments	(783,876)	(1,097,116)
Proceeds from sale of investments	1,027,288	1,263,211
Purchase of capital assets	<u>(5,492)</u>	<u>(14,055)</u>
	237,920	152,040
Net increase (decrease) in cash	538,453	(315,563)
Cash, beginning of year	<u>163,069</u>	<u>478,632</u>
Cash, end of year	\$ 701,522	\$ 163,069

See accompanying notes to the financial statements.

Canadian Liver Foundation

Notes to the Financial Statements

December 31, 2018

1. Nature of operations

Canadian Liver Foundation (the “Foundation”) was formed in 1969 under the laws of the Province of Ontario. In 1989, the Foundation was dissolved and its assets were transferred to another foundation with the same name incorporated under the Canada Corporations Act as a not-for-profit organization without share capital. The Foundation continued under the Canada Not-for-profit Corporations Act in 2014.

The objectives of the Foundation are to provide support for research and education in the causes, diagnosis, prevention and treatment of diseases of the liver. Programs have been designed by the Medical Advisory Board of the Foundation to support the training and research of Canadian investigators and for the further education of both the scientific community and the public. All programs are co-ordinated nationally to promote the most efficient use of available funds. The Foundation has established volunteer Chapters across Canada.

The Foundation is registered as a charity under Section 149(1)(f) of the Income Tax Act (Canada) and, as such, is exempt from income taxes.

2. Summary of significant accounting policies

These financial statements reflect the combined activity and financial position of the Foundation’s National Office and its volunteer Chapters across Canada. The significant accounting policies followed in preparation of these financial statements are as follows:

Basis of presentation

The Foundation has prepared these financial statements in accordance with Canadian accounting standards for not-for-profit organizations (“ASNPO”).

Revenue and expenditure recognition

The accrual basis of accounting is used for reporting revenue and expenditure, except for unrestricted donations and bequests, which are accounted for on a cash basis unless the amount can be reasonably estimated and ultimate collection is reasonably assured.

Research projects are typically funded over a two to three year period, and therefore the revenue related to these projects is recorded on the accrual basis if ultimate collection is reasonably assured.

Research grants are accounted for as an expenditure on an annual basis in accordance with the terms of the respective funding agreements.

Fund accounting

The activities of the Foundation are accounted for utilizing the concepts of restricted fund accounting. Accordingly, three funds – General Fund, Research Trust Funds, and an internally restricted Medical Research Fund – have been established to account for the activities described below:

Canadian Liver Foundation

Notes to the Financial Statements

December 31, 2018

2. Summary of significant accounting policies (continued)

Fund accounting (continued)

The **General Fund** reflects the health promotion, patient support, public information, fundraising and administration activities of the Foundation. Accordingly, all revenue received and expenditures incurred for these purposes, together with all unrestricted donations received are recorded in this fund.

The **Research Trust Funds** comprise the following twenty one externally restricted funds:

W.P. Gilbride Research Trust Fund was created in 1981 in memory of a past president through donations made to the Foundation, specifically to sponsor the W.P. Gilbride Visiting Scientists program.

Sarah Ralston Endowment Fund was established in 1993 in memory of Sarah Ralston. Contributions to this Fund are applied to paediatric liver research.

Chair of Hepatology Trust Fund was created in 1995 to fund research studies at the St. Luc Hospital Hepatology Department affiliated with the University of Montreal.

CanHepC (formally known as Hepatitis C Program) was established in 2000 through Health Canada to enhance existing programs, as well as to provide new programs and services to people living with hepatitis C. In addition, the Foundation received funding to develop and distribute hepatitis C medical information to 35,000 Canadian physicians by mail. In 2002, the NCRTP-Hep C Trust Fund was established to support a national, multi-centre, trans-disciplinary program created to enhance research, training and knowledge translation in the area of hepatitis C. In July 2015, the NCRTP-HepC program expanded the research program further and re-established itself as the Canadian Network on Hepatitis C (CanHepC). The main objective of the CanHepC is to establish a continuous pipeline from discovery to implementation to reduce hepatitis C transmission, cure and improve the quality of life of people with hepatitis C, and to work towards the elimination of hepatitis C infection in Canada.

Raj Bhargava Endowment Fund was established in 2001 in memory of Raj Bhargava. Contributions to this fund are applied to research in the area of radiology of liver disease at the University of Alberta.

CPHRG Trust Fund was established in 2008 to support research in the area of paediatric hepatology including, but not limited to research on biliary atresia, paediatric autoimmune hepatitis and primary sclerosing cholangitis.

Canadian Liver Foundation

Notes to the Financial Statements

December 31, 2018

2. Summary of significant accounting policies (continued)

Fund accounting (continued)

CASL Trust Fund was established in 2008 as a collaborative partnership agreement between Canadian Liver Foundation and CASL (Canadian Association for the Study of Liver) to support the development and management of mutually agreeable research, education and advocacy programs.

MUHC Trust Fund was established in 2008 as a collaborative partnership agreement to support research and education at the McGill University Health Centre in Montreal, Quebec.

Kenroc Trust Fund was established in 2008 to support liver cancer research with funds provided by Kenroc Building Materials Co. Ltd., a Western Canada based construction company.

CLF-Dalhousie Digestive Care & Endoscopy Trust Fund was established in 2012 as a cooperative partnership agreement to support research and training with the Dalhousie University Division of Gastroenterology in Halifax, Nova Scotia.

Canadian Liver Research Group Trust Fund was established in 2010 to support a national, multi-centre project created to increase research investment and resources and to address patient care treatment issues in Canada. The fund had no activity in the year ended December 31, 2018 and had a \$Nil balance at year end.

CLF-Lee Liver Research Trust Fund was established in 2011 as a cooperative partnership agreement to support mutually-agreeable liver research initiatives under the leadership of Dr. Samuel Lee.

Sexton Liver Cancer Research Trust Fund was established in 2012 to support designated liver cancer research with donations from Ken Sexton of Regina, Saskatchewan. The fund had no activity in the year ended December 31, 2018 and had a \$Nil balance at year end.

CLF-CNTRP Trust Fund was established in 2012 as a cooperative partnership agreement with the Canadian National Transplant Research Program (CNTRP) to enhance the survival and quality of life of Canadians needing transplantation, through multi-disciplinary, collaborative and leading-edge research.

CLF-RECAP Trust Fund was established in 2014 as a cooperative partnership agreement with the Centre for Research, Education & Clinical Care of At-Risk Populations (R.E.C.A.P.) to research the health outcomes of a collaborative model of primary and specialized care with the objective of developing a cost-effective model of care for the prevention and management of hepatitis C in New Brunswick.

Canadian Liver Foundation

Notes to the Financial Statements

December 31, 2018

2. Summary of significant accounting policies (continued)

Fund accounting (continued)

CLTN-CLF Trust Fund was established in 2015 as a cooperative partnership agreement between the CLF and the Canadian Liver Transplant Network (CLTN) to support mutually-agreeable liver transplant research, education and advocacy programs.

The **CLF-Krahn Liver Research Trust Fund** was established in 2012 as a cooperative partnership agreement to support mutually-agreeable liver research initiatives under the leadership of Dr. Murray Krahn.

The **CCC-CLF Trust Fund** was established in 2016 as a cooperative partnership agreement between the CLF and the Cirrhosis Care Clinic based in Edmonton, Alberta to support mutually-agreeable liver research, education & patient support programs.

The **CaNAL-CLF Trust Fund** was established in 2017 as a cooperative partnership agreement between the CLF and the Canadian Network for Autoimmune Liver Disease (CaNAL) to support mutually-agreeable liver research projects.

The **HepB Study Group-CLF Trust Fund** was established in 2017 as a cooperative partnership agreement between the CLF and Principle Investigators Drs. Peter Kwan and Francis Ho to support the “H Be Proactive” Study on hepatitis B prevalence in the Greater Vancouver Area.

The **CLF-Canadian Liver Meeting Trust Fund** was established in 2017 as a cooperative partnership agreement between the CLF and the Canadian Association for the Study of the Liver (CASL) to support the Canadian Liver Meeting, which is a national liver medical conference delivering mutually-agreeable liver research and education objectives.

The **Medical Research Fund** was established in 1990 to account for medical research projects established by the Board of Directors and supported primarily by the unrestricted funds of the Foundation. Donations received to fund specific medical research projects are also reflected in this fund.

Donated services and materials

These financial statements do not reflect the substantial value of services received during the year due to difficulties in determining the fair value. Donated materials are recorded as revenue when sold.

Capital assets and amortization

Furniture, fixtures and equipment are amortized using the straight line method over 5 years. Leasehold improvements are amortized on a straight-line basis over the term of the lease.

Canadian Liver Foundation

Notes to the Financial Statements

December 31, 2018

2. Summary of significant accounting policies (continued)

Deferred lease inducements

Deferred lease inducements are amortized over the 10 year term of the lease.

Use of estimates

The preparation of financial statements in accordance with ASNPO requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates. These estimates are based on management's best efforts and knowledge of current events and actions the Foundation may undertake. Significant estimates in these financial statements include the allocation of general fund expenses (Note 9).

Financial instruments

Initial measurement

The Foundation's financial instruments are measured at fair value when issued or acquired. For financial instruments subsequently measured at cost or amortized cost, fair value is adjusted by the amount of the related financing fees and transaction costs. Transaction costs and financing fees relating to financial instruments that are measured subsequently at fair value are recognized in operations in the year in which they are incurred.

Subsequent measurement

At each reporting date, the Foundation measures its financial assets and liabilities at cost or amortized cost (less impairment in the case of financial assets), except for equities quoted in an active market, which must be measured at fair value. The Foundation has also irrevocably chosen to measure its investments in bonds and other fixed income instruments at fair value. All changes in fair value of the Foundation's investments in equities quoted in an active market and in bonds are recorded in the statement of operations. The Foundation uses the effective interest rate method to amortize any premiums, discounts, transaction fees and financing fees to the statement of operations for items measured at cost or amortized cost. The financial instruments measured at amortized cost are cash, accounts receivable and payables.

For financial assets measured at cost or amortized cost, the Foundation regularly assesses whether there are any indications of impairment. If there is an indication of impairment, and the Foundation determines that there is a significant adverse change in the expected timing or amount of future cash flows from the financial asset, it recognizes an impairment loss in the statement of operations. Any reversals of previously recognized impairment losses are recognized in operations in the year the reversal occurs.

Allocation of expenses

The Foundation engages in research and education programs. The costs of each program include costs directly related to providing the program, as well as an allocation of a number of general support expenses relating to personnel, premises and computer outsourcing that are common to the administration of the Foundation. Salaries and benefits are allocated to programs based on staff estimates of time spent on each functional area. Office rent and computer outsourcing costs are allocated between departments based on headcount and functional area. Fundraising costs are not allocated.

Canadian Liver Foundation

Notes to the Financial Statements

December 31, 2018

3. Restricted cash

Included in cash is \$215,822 (2017 - \$65,211) that was earned in gaming revenues, and which is restricted by the local authorities for use in the province where the gaming revenues were earned.

4. Investments

	<u>2018</u>	<u>2017</u>
Bonds	\$ 1,477,911	\$ 1,592,329
Equities	2,734,086	2,826,114
Units in income trusts	<u>441,517</u>	<u>484,622</u>
	<u>\$ 4,653,514</u>	<u>\$ 4,903,065</u>

Investments are stated at fair value at year end and have an original cost of \$4,055,814 (2017 - \$4,119,713).

5. Capital assets

	<u>Cost</u>	<u>Accumulated Amortization</u>	<u>2018 Net Book Value</u>	<u>2017 Net Book Value</u>
Furniture, fixtures and equipment	\$ 150,047	\$ 126,397	\$ 23,650	\$ 24,070
Leasehold improvements	<u>438,768</u>	<u>398,345</u>	<u>40,423</u>	<u>54,949</u>
	<u>\$ 588,815</u>	<u>\$ 524,742</u>	<u>\$ 64,073</u>	<u>\$ 79,019</u>

6. Research commitments

The Foundation has awarded a number of multi-year research grants which will be funded as the research progresses and agreed reporting criteria have been met. Funding committed in future years is as follows:

2019	\$ 656,464
2020	240,000
2021	<u>60,000</u>
	<u>\$ 956,464</u>

Subsequent to year end, at its January 2019 meeting, the Board committed to fund \$315,500 for new Liver Research in Canada projects subject to peer review by the Foundation's Medical Advisory Committee. These commitments are reflected in the total research commitments of \$956,464.

Canadian Liver Foundation

Notes to the Financial Statements

December 31, 2018

7. Commitments

In addition to the research commitments described in Note 6, at December 31, 2018, minimum lease payments under operating leases for rental of premises and equipment over the next five fiscal years approximate the following:

2019	\$	284,687
2020		160,517
2021		123,161
2022		33,823
2023		16,699
	\$	<u>618,887</u>

The above commitments schedule includes the National lease which has 33 months remaining in the term.

8. Additional information required to meet Alberta Government and Program Support Services financial statement disclosure requirements

The total amount paid as remuneration to employees of the Foundation whose principal duties involve fundraising was \$397,965 (2017 - \$417,576). The amounts paid as remuneration to a fundraising business, including expenses or fees paid by the Foundation on behalf of the fundraising business or as reimbursements to the fundraising business was \$1,003,163 (2017 - \$942,789).

9. General fund expense allocation

	<u>Chapter</u>	<u>Gaming</u>	<u>Education</u>	<u>Public information</u>	<u>Fundraising</u>	<u>Administration</u>	<u>2018</u>
Direct costs	\$ 32,984	\$ 18,678	\$ 254,645	\$ 177,566	\$ 1,348,581	\$ 349,175	\$ 2,181,629
Allocated costs							
Salaries and							
Benefits	194,974	-	406,169	218,469	194,232	916,228	1,930,072
Office rent	-	-	67,860	33,930	16,965	92,470	211,225
Computer							
Outsourcing	-	-	34,303	17,394	8,575	43,670	103,942
Total	<u>\$ 227,958</u>	<u>\$ 18,678</u>	<u>\$ 762,977</u>	<u>\$ 447,359</u>	<u>\$ 1,568,353</u>	<u>\$ 1,401,543</u>	<u>\$ 4,426,868</u>
	<u>Chapter</u>	<u>Gaming</u>	<u>Education</u>	<u>Public information</u>	<u>Fundraising</u>	<u>Administration</u>	<u>2017</u>
Direct costs	\$ 81,809	\$ 9,709	\$ 330,202	\$ 215,243	\$ 1,394,494	\$ 372,155	\$ 2,403,612
Allocated costs							
Salaries and							
Benefits	157,977	-	383,607	205,611	306,870	770,986	1,825,051
Office rent	-	-	67,035	32,848	16,759	92,474	209,116
Computer							
Outsourcing	-	-	35,934	17,667	9,085	49,187	111,873
Total	<u>\$239,786</u>	<u>\$ 9,709</u>	<u>\$ 816,778</u>	<u>\$ 471,369</u>	<u>\$1,727,208</u>	<u>\$ 1,284,802</u>	<u>\$ 4,549,652</u>

Canadian Liver Foundation

Notes to the Financial Statements

December 31, 2018

10. Letter of credit

The Foundation has access to a revolving demand credit facility bearing interest at Royal Bank of Canada prime rate plus 3.0% per annum (6.95% at December 31, 2018) to a maximum of \$100,000. The facility is secured by a general security agreement over all property. The balance outstanding under this facility was \$Nil (2017 - \$Nil) at year end.

11. Financial instrument risk

The Foundation is exposed to various risks through its financial instruments. The following analysis provides a measure of the Foundation's risk exposure and concentrations at December 31, 2018.

Credit risk

Credit risk arises as a result of the potential non-performance by counterparties of contract obligations which could lead to a financial loss to the Foundation. The Foundation's credit risk relates to its accounts receivable. In the opinion of management, the credit risk exposure to the Foundation is not significant due to the nature of its accounts receivable.

Liquidity risk

Liquidity risk is the risk that the Foundation will encounter difficulty in meeting its obligations. The Foundation meets its liquidity requirements by preparing and monitoring detailed forecasts of cash flows from operations, anticipating investing and financing activities and holding assets that can be readily converted into cash.

Market risk

Market risk is the risk that the fair value of or expected future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise of three types of risk: interest rate risk, currency risk, and other price risk.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows from a financial instrument will fluctuate because of market changes in interest rates. The Foundation is subject to interest rate risk on its fixed income instruments, as disclosed in Note 4.

Currency risk

Currency risk is the risk that the fair value of or future cash flows from a financial instrument denominated in currencies other than the functional currency of the Foundation will fluctuate due to changes in foreign exchange rates. The Foundation is exposed to currency risk as it invests in foreign currency bonds and equities totaling USD \$1,078,945 (2017 – USD \$1,073,560), which are converted to the Foundation's functional currency (i.e. Canadian dollars) in determining fair value. Accordingly any change in fair value includes an element of foreign currency translation gain/loss as well as underlying change in market values for the foreign currency investments.

Other price risk

Other price risk is the risk that the fair value of or future cash flows from a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. The Foundation is not subject to other price risks.

Canadian Liver Foundation

Schedule of Research Trust Funds

Year ended December 31

	W.P. Gilbride		Sarah Ralston		Chair of Hepatology		CanHepC		Raj Bhargava	
	2018	2017	2018	2017	2018	2017	2018	2017	2018	2017
Balance, beginning of year	\$ 181,800	\$ 180,602	\$ 137	\$ 2,850	\$ 6,010	\$ 6,010	\$ 922,211	\$ 1,295,380	\$ 1,115	\$ 3,919
Transfer to Medical Research Fund in support of research	(10,000)	(10,000)	-	(3,000)	-	-	-	-	-	(4,000)
Contributions	-	-	-	-	-	-	88,000	269,235	-	-
Chapter donations	-	-	-	-	-	-	-	-	-	-
Investment income	95	11,198	2	287	-	-	(1,337)	76,483	52	1,196
Program costs	-	-	-	-	-	-	(112,495)	(718,887)	-	-
Balance, end of year	<u>\$ 171,895</u>	<u>\$ 181,800</u>	<u>\$ 139</u>	<u>\$ 137</u>	<u>\$ 6,010</u>	<u>\$ 6,010</u>	<u>\$ 896,379</u>	<u>\$ 922,211</u>	<u>\$ 1,167</u>	<u>\$ 1,115</u>

	CPHRG		CASL		MUHC		Hep B Study Group		CLF-Dalhousie	
	2018	2017	2018	2017	2018	2017	2018	2017	2018	2017
Balance, beginning of year	\$ 5,879	\$ 5,361	\$ 574,866	\$ 623,784	\$ 104,793	\$ 95,594	\$ 370,058	\$ -	\$ 33,528	\$ 25,952
Transfer to Medical Research Fund in support of research	-	-	-	-	-	-	-	-	-	-
Contributions	-	-	471,233	245,008	1,500	2,500	-	-	-	-
Chapter donations	-	-	-	-	-	-	100,000	350,000	-	-
Investment income	5	518	334	46,183	74	8,682	(631)	25,060	5,083	7,576
Program costs	-	-	(362,717)	(340,109)	-	(1,983)	(260,786)	(5,002)	-	-
Balance, end of year	<u>\$ 5,884</u>	<u>\$ 5,879</u>	<u>\$ 683,716</u>	<u>\$ 574,866</u>	<u>\$ 106,367</u>	<u>\$ 104,793</u>	<u>\$ 208,641</u>	<u>\$ 370,058</u>	<u>\$ 38,611</u>	<u>\$ 33,528</u>

Canadian Liver Foundation

Schedule of Research Trust Funds (continued)

Year ended December 31

	Liver Meeting		CLF-Lee Liver Research		CLF-CNTRP		Kenroc		CLF - RECAP	
	2018	2017	2018	2017	2018	2017	2018	2017	2018	2017
Balance, beginning of year	\$ 269,881	\$ -	\$ 11,400	\$ 11,400	\$ 1,214,375	\$ 1,027,380	\$ 4,562	\$ 6,317	\$ 4,324	\$ 3,374
Transfer to Medical Research Fund in support of research	-	-	-	-	-	-	(107,500)	(95,000)	-	-
Contributions	110,000	270,000	-	-	642,841	548,548	107,514	84,140	29	950
Chapter donations	-	-	-	-	-	-	-	-	-	-
Investment income	-	-	-	-	(5,778)	94,164	3,293	9,105	-	-
Program costs	(379,881)	(119)	-	-	(293,319)	(455,717)	-	-	(2)	-
Balance, end of year	\$ -	\$ 269,881	\$ 11,400	\$ 11,400	\$ 1,558,119	\$ 1,214,375	\$ 7,869	\$ 4,562	\$ 4,351	\$ 4,324

	CLTN-CLF		CLF - Krahn		CaNAL-CLF		CCC-CLF		Total	
	2018	2017	2018	2017	2018	2017	2018	2017	2018	2017
Balance, beginning of year	\$ 51,856	\$ 69,371	\$ -	\$ -	\$ 161,988	\$ -	\$ 23	\$ -	\$ 3,918,805	\$ 3,357,293
Transfer to Medical Research Fund in support of research	-	-	-	-	-	-	-	-	(117,500)	(112,000)
Contributions	-	5,000	350,000	400,000	304,198	280,435	4,750	95	2,080,065	2,105,911
Chapter donations	-	-	-	-	-	-	-	-	100,000	350,000
Investment income	110	4,553	-	-	(2,490)	624	-	-	(1,188)	285,629
Program costs	(2,872)	(27,068)	(350,000)	(400,000)	(268,530)	(119,071)	(72)	(72)	(2,030,674)	(2,068,028)
Balance, end of year	\$ 49,094	\$ 51,856	\$ -	\$ -	\$ 195,166	\$ 161,988	\$ 4,701	\$ 23	\$ 3,949,508	\$ 3,918,805